PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7195707

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
TAKEDA CALIFORNIA, INC.	09/12/2016

RECEIVING PARTY DATA

Name:	TAKEDA PHARMACEUTICAL COMPANY LIMITED	
Street Address:	1-1, DOSHOMACHI 4-CHOME, CHUO-KU, OSAKA-SHI	
City:	OSAKA	
State/Country:	JAPAN	
Postal Code:	541-0045	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17560522

CORRESPONDENCE DATA

Fax Number: (202)842-7899

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6179372300

Email: jvecchia@cooley.com

Correspondent Name: COOLEY LLP, ATTN: PATENT GROUP Address Line 1: 1299 PENNSYLVANIA AVENUE, NW

Address Line 2: SUITE 700

Address Line 4: WASHINGTON, D.C. 20004

ATTORNEY DOCKET NUMBER:	RSLV-013C01US 344300-2327	
NAME OF SUBMITTER:	ERIKA L. WALLACE	
SIGNATURE:	/ Erika L. Wallace /	
DATE SIGNED:	02/25/2022	

Total Attachments: 2

source=Executed Takeda California to Takeda Pharmaceutical, Inc. Assignment RSN-018US 4847-2055-0788 2#page1.tif

source=Executed Takeda California to Takeda Pharmaceutical, Inc. Assignment

RSN-018US 4847-2055-0788 2#page2.tif

PATENT REEL: 059104 FRAME: 0126

507148863

Serial Number: 16/313,656

Docket No. RSLV-5003-P

ASSIGNMENT

WHEREAS, I/WE

Takeda California, Inc.

hereinafter referred to as Assignor(s), have invented a certain invention entitled:

OPTIMIZED BINUCLEASE FUSIONS AND METHODS

for which invention an application (provisional or non-provisional) for a U.S. patent was filed on July 1, 2016, under U.S. Application No. 62/357,756, and

WHEREAS, **Takeda Pharmaceutical Company Limited** of 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 Japan, hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in, to, and under the invention described in the patent application, including the entire priority right derived from the application,

Now, Therefore, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor(s) assign and transfer to Assignee and Assignee's legal representatives, successors, and assigns the entire right, title, and interest in, to, and under the invention, the referenced patent application, and other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, and utility model applications) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, and the patents that may issue thereon,

Assignor(s) convey to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor(s) will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor(s) will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the patent applications identified herein, including, but not limited to,

rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor(s) and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor(s) authorize Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto.

Assignor(s) and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment, as evidenced by the signature of an officer or authorized representative of Assignee below.

IN WITNESS WHEREOF, Assignor has hereunder set his/her hand on the date shown below.

Date <u>Deptember 12,2016</u>

David J. Weitz

DaisWer

Head of Takeda California and Global Research

Externalization